Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.
about
Toll-like receptor 3 transmembrane domain is able to perform various homotypic interactions: an NMR structural studyInterleukin-1 in the pathogenesis and treatment of inflammatory diseasesStructural basis of TLR5-flagellin recognition and signalingAdjuvants: Classification, Modus Operandi, and LicensingMolecular and cellular regulation of toll-like receptor-4 activity induced by lipopolysaccharide ligandsTargeting toll-like receptor signaling as a novel approach to prevent ocular infectious diseasesCo-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signalingControversial role of toll-like receptors in acute pancreatitisControlling complexity: the clinical relevance of mouse complex geneticsInternational Union of Basic and Clinical Pharmacology. XCVI. Pattern recognition receptors in health and diseaseHistone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophagesRO 90-7501 enhances TLR3 and RLR agonist induced antiviral responseIsolated Toll-like receptor transmembrane domains are capable of oligomerizationB-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3KMyeloid-specific Rictor deletion induces M1 macrophage polarization and potentiates in vivo pro-inflammatory response to lipopolysaccharideRegulation of the innate immune response by fibronectin: synergism between the III-1 and EDA domainsPre-treatment of recombinant mouse MFG-E8 downregulates LPS-induced TNF-α production in macrophages via STAT3-mediated SOCS3 activationToll Like Receptors Signaling Pathways as a Target for Therapeutic InterventionsStructural dynamic analysis of apo and ATP-bound IRAK4 kinaseGlutathione peroxidase-1 primes pro-inflammatory cytokine production after LPS challenge in vivo.Use of a single-chain antibody library for ovarian cancer biomarker discovery.Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening.Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasisTrace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins.The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists.Activated TLR signaling in atherosclerosis among women with lower Framingham risk score: the multi-ethnic study of atherosclerosis.Selective antibody intervention of Toll-like receptor 4 activation through Fc γ receptor tethering.The association of toll-like receptor 4 polymorphism with hepatitis C virus infection in Saudi Arabian patients.Signatures of positive selection in Toll-like receptor (TLR) genes in mammals.Differential induction of innate immune responses by synthetic lipid a derivativesLigand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunityInactivated vaccine with adjuvants consisting of pattern recognition receptor agonists confers protection against avian influenza viruses in chickens.Rationally Designed Macrocyclic Peptides as Synergistic Agonists of LPS-Induced Inflammatory ResponseTherapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malariaBlocking TLR2 in vivo protects against accumulation of inflammatory cells and neuronal injury in experimental stroke.Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.Oxidized low density lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via Toll-like receptors 2 and 4.A novel 1,2-benzenediamine derivative FC-99 suppresses TLR3 expression and ameliorates disease symptoms in a mouse model of sepsis
P2860
Q24304035-02F38AB1-7F4A-4DBF-8889-564A6CF81EA3Q24606766-70F496F9-87A9-4D74-9C66-740FD42BE6A9Q24628830-B9CFCE64-2EE1-46F4-A072-917AB62BA31BQ26747586-743CEE99-8AC1-4706-972A-83B46E0279ECQ26827187-5EF66E0F-13CC-46C4-B5E3-624258B082E8Q26849739-3A0F1811-C735-4065-A13C-CED0A98BDFF4Q26866939-10592ACB-1D71-4805-A591-1BEAECF87F24Q27025519-8403191A-1CD8-46EB-A664-11C4D5C413B6Q27027931-3D7868F4-1675-4B3B-9069-1A9B14C65A39Q28081406-AD562A95-7457-42F6-A5BA-461123F471D9Q28294510-71E596DE-FCDD-4123-B9AF-30C39C40E7E4Q28484218-34640743-A931-42DC-94C7-EC17B500286FQ28485183-53860753-6897-4FD5-87EB-B6D56B89550CQ28510899-9D1DDFC3-2E3C-460B-AC24-02B795D7D27BQ28513075-C73B48A9-DDAE-4E17-B562-C1CE56C1EF1FQ28541049-746AAD9C-D62C-4423-A313-81390ECCBFF5Q28742712-B4980867-D178-4487-B04E-584F84B0AC6FQ29248835-3D7AC7A9-0F33-42CA-8AD1-E9235C2D87D5Q30584224-E457843B-9E1C-41FA-8F0A-2A4F25B29FBBQ31050906-A28E79E0-8289-4827-8AF4-D915104ADBE4Q33577786-369B5077-2D39-404C-9DCC-8BF6EE71DD2AQ33588328-781BE770-13D0-479B-8A04-496F06792EDFQ33743450-6DB37F99-3ED7-43ED-8392-52A86576125BQ33762632-969E2C8D-813B-49F2-8DDF-8AE311E56C3EQ33784812-DA32F7A2-D24D-42A0-91AD-2EB445ADFFB3Q33825555-E5AEC597-DF46-4FE4-90D3-36A0D2ADB186Q33914745-9C931F9A-BE3E-40EB-AC4D-BC8EF90ECB82Q33940856-F8A22013-75F3-4630-8414-69520D9F90F2Q34075883-584E2E49-ACDD-43B3-B1B6-3D4D0F41A19FQ34081261-D87C2DCE-DD94-4913-849B-887436FE058EQ34106795-893C97D1-AC40-450B-9BCE-7F85B1AA1381Q34121591-A058FF5E-EE39-4E69-9583-3049660ECE2FQ34153811-50C440A1-E29B-4671-87F3-24B5AAE730F8Q34400303-96E68549-4882-4B82-B7F7-11AFBF83A57CQ34493434-5102E866-4B90-455D-A06C-D76503BE0C23Q34621573-28F3810C-D475-462D-9E58-A1691B8CAF2CQ34627666-1E3F5417-D557-4C92-9665-DF09A2EB2F03Q34672043-DA347FF4-C48A-4FAE-A58B-0194117DDB46Q34752149-AFB06C43-6100-4337-9ABC-65564D7FACA3Q34954047-6B0D5EE8-E7BE-4700-8625-3EA7917295F9
P2860
Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic targeting of Toll- ...... lammatory diseases and cancer.
@en
Therapeutic targeting of Toll- ...... lammatory diseases and cancer.
@nl
type
label
Therapeutic targeting of Toll- ...... lammatory diseases and cancer.
@en
Therapeutic targeting of Toll- ...... lammatory diseases and cancer.
@nl
prefLabel
Therapeutic targeting of Toll- ...... lammatory diseases and cancer.
@en
Therapeutic targeting of Toll- ...... lammatory diseases and cancer.
@nl
P2860
P356
P1476
Therapeutic targeting of Toll- ...... flammatory diseases and cancer
@en
P2093
Clare E Bryant
P2860
P304
P356
10.1124/PR.109.001073
P577
2009-05-27T00:00:00Z